Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical research in partnership with Applied Radiology.
The website is specifically designed for healthcare professionals such as physicians and technologists, and features case studies, webinars, and technologist education.
The launch of TelixU coincides with this year’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, and with over 20 sessions on gallium-68 (68Ga), the website will be a welcome resource for those looking for more information about prostate specific membrane antigen (PSMA) targeted radiopharmaceuticals.
“We are proud to support SNMMI and their endeavors to educate physicians and their membership,” says Dr. Colin Hayward, MBBS FFPM, Chief Medical Officer, Telix Pharmaceuticals. “Our participation in this year’s Virtual Annual Meeting is an ideal platform to introduce this valuable resource.”
The Case Studies section provides peer-to-peer insight about PSMA PET/CT imaging, whilst ‘Technologist Education’ is a wide-ranging resource for anyone delivering PSMA imaging services and includes patient considerations, PET/CT imaging protocols, and operational and workflow resources.
“Applied Radiology is delighted to support Telix in this endeavor,” said Kieran Anderson, Vice President and Group Publisher at Anderson Publishing Ltd., publishers of Applied Radiology and Applied Radiation Oncology. “We have a long history of working closely with key opinion leaders and industry. We develop high-quality, informative, and engaging content, and TelixU is the latest example, as it builds on our continued commitment to the medical imaging community”.
TelixU is intended for healthcare professionals only.
To read the press release please click here.
To visit the TelixU website please click here.
To return to Telix’s homepage please click here.